Latest News
MaaT Pharma’s GvHD drug boasts 18-month overall survival improvement
Lyon, France-based MaaT Pharma has announced positive 18-month data for its lead candidate MaaT013 showing an overall survival advantage in…
Lipocine hopes obesity drug could boost muscle mass in combo with GLP1-RAs
Lipocine hopes its obesity candidate LPCN 2401 could work alongside glucagon-like peptide-1 receptor agonists (GLP1-RAs) to help improve muscle mass…
Amylyx announces positive results for failed ALS drug in Wolfram trial
Just one week after pulling its lead candidate Relyvrio from the market for amyotrophic lateral sclerosis (ALS), Amyyx Pharmaceuticals has…
Ocugen to initiate Phase III trial of gene therapy for retinitis pigmentosa
Ocugen will soon be initiating a Phase III trial of its gene therapy candidate OCU400 for retinitis pigmentosa (RP). The…
FDA gives nod to BrainStorm for ALS trial after Phase III flop
BrainStorm Cell Therapeutics will be initiating a Phase IIIb confirmatory trial of its lead candidate NurOwn after discussions with the…